―2015年―

H Murai
What should we target? The beginning of a new era in the diagnosis and treatment of myasthenia gravis
Clinical and Experimental Neuroimmunology, 2015, 6: 3-4

H Murai
Japanese clinical guidelines for myasthenia gravis: Putting into practice
Clinical and Experimental Neuroimmunology, 2015, 6: 21-31

K Utsugisawa, Y Nagane,T Imai, M Motomura,M Masuda, S Konno,S Suzuki
Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes
Clinical and Experimental Neuroimmunology, 2015, 6: 195-200

Konno S, Suzuki S, Masuda M, Nagane Y, Tsuda E, Murai H, Imai T, Fujioka T, Suzuki N, Utsugisawa K.
Asociation between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study.
PLoS One. 2015 May 12;10(5):e0126579. doi: 10.1371/journal.pone.0126579. eCollection 2015.
abstract

Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M, Konno S, Suzuki Y, Nakane S, Fujihara K, Suzuki N, Utsugisawa K.
Oral corticosteroid therapy and present disease status in myasthenia gravis.
Muscle Nerve. 2015 May;51(5):692-6. doi: 10.1002/mus.24438. Epub 2015 Feb 4.
abstract

―2014年―

Akaishi T, Yamaguchi T, Suzuki Y, Nagane Y, Suzuki S, Murai H, Imai T, Motomura M, Fujihara K, Aoki M, Utsugisawa K.
Insights into the classification of myasthenia gravis.
PLoS One. 2014 Sep 5;9(9):e106757. doi: 10.1371/journal.pone.0106757. eCollection 2014.
abstract

Ikeguchi R, Shimizu Y, Suzuki S, Shimizu S, Kabasawa C, Hashimoto S, Masuda M, Nagane Y, Utsugisawa K, Suzuki Y, Takahashi T, Utsumi H, Fujihara K, Suzuki N, Uchiyama S.
Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature.
Clin Neurol Neurosurg. 2014 Oct;125:217-21. doi: 10.1016/j.clineuro.2014.07.036. Epub 2014 Aug 20.
abstract

Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, Konno S, Oji S, Nakane S, Motomura M, Suzuki N, Utsugisawa K.
Quality of life in purely ocular myasthenia in Japan.
BMC Neurol. 2014 Jul 5;14:142. doi: 10.1186/1471-2377-14-142.
abstract

Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, Konno S, Oji S, Nakane S, Motomura M, Suzuki N, Utsugisawa K.
Quality of life in purely ocular myasthenia in Japan.
BMC Neurol. 2014 Jul 5;14:142. doi: 10.1186/1471-2377-14-142.
abstract

Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Murai H, Imai T, Tsuda E, Konno S, Nakane S, Suzuki Y, Fujihara K, Suzuki N.
Health-Related Quality of Life and Treatment Targets in Myasthenia Gravis.
Muscle Nerve. 2014, in press.
abstract

Murai H, Masuda M, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M, Konno S, Kira J.
Clinical features and treatment status of adult myasthenia gravis in Japan.
Clinical and Experimental Neuroimmunology 2014; doi: 10.1111/cen3.12091.
abstract

Shimizu Y, Suzuki S, Utsugisawa K, Imai T, Murai H, Nagane Y, Tsuda E, Nagasao T, Ogata H, Yazawa M, Suzuki N, Kishi K.
Is surgical intervention safe and effective in the treatment of myasthenic blepharoptosis? A multicenter survey in Japan.
Eur Neurol. 2014; 71: 259-261.
abstract

Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, Suzuki N.
Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies.
Eur J Neurol. 2014; 2: 223-230.
abstract

―2013年―

Suzuki S, Nishimoto T, Kohno M, Utsugisawa K, Nagane Y, Kuwana M, Suzuki N.
Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis.
J Neuroimmunol. 2013;258:61-6.
abstract

―2012年―

Suzuki S, Utsugisawa K, Suzuki N.
Overlooked non-motor symptoms in myasthenia gravis.
J Neurol Neurosurg Psychiatry. 2012;84:989-94.
abstract

Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda M, Fukuda T,Yoshimura T, Tsujihata M, Kawakami A. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis.
J Neurol Neurosurg Psychiatry. 2012;83:935-40.
abstract

Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, Shimizu Y, Utsumi H, Fujihara K, Uchiyama S, Suzuki N.
The MG-QOL15 Japanese version: validation and associations with clinical factors.
Muscle Nerve. 2012;46:166-73.
abstract

Kabasawa C, Shimizu Y, Suzuki S, Masuda M, Nagane Y, Utsugisawa K, Suzuki Y, Utsumi H, Uchiyama S, Fujihara K, Suzuki N, Uchiyama S.
Taste disorders in myasthenia gravis: a multicenter cooperative study.
Eur J Neurol 2012;20:205-7.
abstract

―2011年―

Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, Shimizu Y, Utsumi H, Uchiyama S, Fujihara K, Suzuki N.
Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study.
BMJ Open 2011; 1: e000313.
abstract

Nishimoto Y, Suzuki S, Utsugisawa K, Nagane Y, Shibata M, Shimizu T, Suzuki N.
Headache associated with myasthenia gravis: the impact of mild ocular symptoms.
Autoimmune Dis 2011; 840364.
abstract

Suzuki S, Utsugisawa K, Nagane Y, Suzuki N.
Three types of striational antibodies in myasthenia gravis.
Autoimmune Dis 2011; 740583.
abstract

Suzuki S, Utsugisawa K, Iwasa K, Satoh T, Nagane Y, Yoshikawa H, Kuwana M, Suzuki N.
Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis.
J Neuroimmunol 2011; 237:87-92.
abstract

Nagane Y, Utsugisawa K, Suzuki S, Masuda M, Shimizu Y, Utsumi H, Uchiyama S, Suzuki N.
Topical naphazoline in the treatment of myasthenic blepharoptosis.
Muscle Nerve 2011; 44: 41-44.
abstract

Nagane Y, Suzuki S, Suzuki N, Utsugisawa K.
Early Aggressive Treatment Strategy against Myasthenia Gravis.
Eur Neurol 2011; 65: 16-22.
abstract

Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N.
Clinical and immunological differences between early and late-onset myasthenia gravis in Japan.
J Neuroimmunol 2011; 230: 148-152.
abstract